A Phase 3 interventional study of PP6M and PP3M 350 mg eq. in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 138 sites in 21 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 41 in phase 3, and was the 99th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 841 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 7th largest by enrollment of the 176 interventional ones that give a count, is one of 2 that started in 2017, is one of 74 in phase 3, and was the 193rd registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants with schizophrenia previously stabilized on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M (350 or 525 mg eq.).
The primary hypothesis of this study is that the efficacy of PP6M is non-inferior to PP3M for preventing relapse in participants with schizophrenia who were previously stabilized on corresponding doses of PP1M or PP3M. The study consists of mainly 3 phases: a screening phase (up to 28 days), a maintenance phase (of 1 or 3 months), and a double-blind phase (of 12 months [neither the researchers nor the participants know what treatment the participant is receiving]). Additional/conditional phases include a transition phase (before maintenance phase). Study evaluations include efficacy, pharmacokinetics, pharmacodynamics, and safety. The study duration will vary from approximately 13 months to 19 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.
Drug: PP1M
All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.
Drug: PP3M 350 mg eq. · Drug: PP3M 525 mg eq. · Drug: PP1M
Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.
Drug: PP6M · Other: Placebo
Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.
Drug: PP3M 350 mg eq. · Drug: PP3M 525 mg eq.
Participants will receive intramuscular injection of PP6M.
Also known as: R092670
Participants will receive intramuscular injection of PP3M 350 mg eq.
Also known as: R092670
Participants will receive intramuscular injection of PP3M 525 mg eq.
Also known as: R092670
Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
Also known as: R092670
Participants will receive matching placebo.
Time to Relapse During the Double-Blind (DB) Phase
Time to relapse is time between participant randomization in DB Phase and first documentation of relapse event by end of Month 12 of DB phase. Relapse is defined as: a) Psychiatric hospitalization; b) Positive and Negative Syndrome Scale (PANSS) total score: Increase of 25 percentage (%), 10 point increase in PANSS for 2 analysis separated by 3-7 days if score was greater than (\>) 40, less than or equal to (\<=)40; c) Participants inflicted knowing self-injury/shown violent behavior leading to suicide, clinically significant injury to him/herself or other person/property; d) Participants had suicidal/homicidal ideation/violent behavior that was clinically significant as per investigator; e) PANSS items P1- delusions, P2- conceptual disorganization, P3-hallucinatory behavior, P6- suspiciousness/ persecution, P7-hostility, G8-uncooperativeness: score: greater than or equal to (\>=)5, \>=6 for 2 analysis separated by 3-7 days on any items if maximum score for PANSS: \<=3 or 4, respectively.
Time frame: Up to 12 months of DB Phase
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale from 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score
CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. A higher score implies a more severe condition.
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Personal and Social Performance (PSP) Scale Total Score
The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.
Time frame: Baseline (DB) to 12 Months of DB Phase
Percentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase
Symptomatic remission was defined as achieving intensity level of mild or moderate on PANSS scale by all 8 items as the determinants for symptomatic remission: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, lack of spontaneity. The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent), 2 (minimal), 3 (mild), 4 (moderate), 5 (moderately severe), 6 (severe) and 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.
Time frame: Up to 12 months of DB Phase
Change From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score
The SPSR Short Form 8a is a participant-reported outcome used to assess the satisfaction with participation in social roles. The participants were asked to rate 8 items on 5-point Likert scale, with scores ranging from 8 to 40, where higher scores represents higher satisfaction.
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score
TSQM-9 consists of 9 questions to assess patients' satisfaction with medication using a range of responses from 1 (extremely dissatisfied) to (7 extremely satisfied). This patient reported outcome provides scores on three parts: effectiveness, convenience, and global satisfaction. The sum of the 9-questions were calculated and used for analysis. The total score ranges from 0 to 63, with higher scores indicating better treatment satisfaction.
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score
The SAS rates 10 items for general extrapyramidal symptoms (EPS) on a 5-point scale from 0 (normal) to 4 (extreme), including gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head rotation, Glabellar tap, tremor, and salivation. The SAS total score is the average score (total sum of item scores divided by the number of items) and ranges between 0 and 4. Negative change in score indicates improvement. Higher scores denote more severe condition of EPS.
Time frame: Baseline (DB) to 12 Months of DB Phase
Number of Participants With Symptoms of Akathisia Assessed Using Barnes Akathisia Rating Scale (BARS) Score
BARS is used to rate observable, restless movements of drug induced akathisia and subjective awareness of restlessness and any distress associated with the akathisia. BARS consists of the following 4 items: objective assessment of akathisia symptoms, subjective assessment of the participants's awareness of inner restlessness, distress restlessness, and global clinical assessment of akathisia. First three items are rated on a 4-point scale ranging from 0 (no abnormal movements or absence of inner restlessness or no distress) to 3 (severe akathisia or awareness of intense compulsion to move most of the time or severe distress). The last item, the global clinical assessment of akathisia, is rated on a 6-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia).
Time frame: Up to 12 Months of DB Phase
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score
AIMS is a 14-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 to 14 are yes/no questions regarding the global judgement and dental status of the participant. The total score is the sum of the scores for the 14 items and the possible total score ranges from 0 to 44. A higher total score is indicative of more severe dyskinetic movements.
Time frame: Baseline (DB) to 12 Months of DB Phase
Number of Participants Based on Columbia Suicide Severity Rating Scale (C-SSRS) Total Score
The C-SSRS is a questionnaire used for suicide risk assessment. Affirmative or negative responses are provided to items 1 to 5 for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods \[not plan\] without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and items 6 to 10 for suicide behavior (6. Preparatory acts or behavior, 7. Aborted attempt, 8. Interrupted attempt, 9. Actual attempt, 10. Completed suicide). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation.
Time frame: Baseline and endpoint (12 Months of DB Phase)
Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values During DB Phase
Number of participants with treatment-emergent abnormal ECG values were reported. It includes heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute (bpm) , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec).
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Body Mass Index (BMI) During DB Phase
Change from baseline in BMI was reported.
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Waist Circumference During DB Phase
Change from baseline in waist circumference was reported.
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Body Weight During DB Phase
Change from baseline in body weight was reported.
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Vital Signs (Pulse Rate) During DB Phase
Change from baseline vital signs (pulse rate) were reported. This included supine pulse rate, standing pulse rate and supine-standing pulse rate.
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) During DB Phase
Change from baseline in vital signs including SBP and DBP (supine/standing) were reported.
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in Positive and Syndrome Scale (PANSS) Subscales Score During DB Phase
The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).
Time frame: Baseline (DB) to 12 Months of DB Phase
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Chemistry During DB Phase
Number of participants with clinically significant abnormal laboratory values in chemistry included alanine aminotransferase (Unit per Litre \[U/L\]), albumin (Gram per Litre \[g/L\]), alkaline phosphatase (U/L), aspartate aminotransferase (U/L), bicarbonate (millimoles per litre \[mmol/L\]), bilirubin (micromoles per litre \[umol/L\]), calcium (mmol/L), chloride (mmol/L), cholesterol (mmol/L), creatinine (umol/L), gamma glutamyl transferase (GGT) (U/L), glucose (mmol/L), high-density lipoproteins (HDL) cholesterol (mmol/L), low density lipoproteins (LDL) cholesterol (mmol/L), lactate dehydrogenase (U/L), phosphate (mmol/L), potassium (mmol/L), protein (mmol/L), sodium (mmol/L), triglycerides (mmol/L), urate (umol/L), urea nitrogen (mmol/L) were reported. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.
Time frame: Up to 12 Months of DB Phase
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Hematology During DB Phase
Number of participants with clinically significant abnormal laboratory values in hematology included hemoglobin (Hb), hematocrit (Hct), red blood cell (RBC) count, white blood cell (WBC) count with differential, platelets, hemoglobin A1c. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.
Time frame: Up to 12 Months of DB Phase
| Milestone | Open-Label (OL) PP1M/PP3M | Double-blind PP3M | Double-blind PP6M | Follow-up (FU) Phase PP3M | Follow-up Phase PP6M |
|---|---|---|---|---|---|
| Started | 838 | 0 | 0 | 0 | 0 |
| Completed | 702 | 0 | 0 | 0 | 0 |
| Not completed | 136 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 30 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Initiated prohibited medication | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 8 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 57 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 15 | 0 | 0 | 0 | 0 |
| Milestone | Open-Label (OL) PP1M/PP3M | Double-blind PP3M | Double-blind PP6M | Follow-up (FU) Phase PP3M | Follow-up Phase PP6M |
|---|---|---|---|---|---|
| Started | 0 | 224 | 478 | 0 | 0 |
| Completed | 0 | 202 | 416 | 0 | 0 |
| Not completed | 0 | 22 | 62 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 6 | 0 | 0 |
| Withdrew: Death | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Initiated prohibited medication | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 7 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 4 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 16 | 38 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 3 | 0 | 0 |
| Milestone | Open-Label (OL) PP1M/PP3M | Double-blind PP3M | Double-blind PP6M | Follow-up (FU) Phase PP3M | Follow-up Phase PP6M |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 42 | 109 |
| Completed | 0 | 0 | 0 | 34 | 78 |
| Not completed | 0 | 0 | 0 | 8 | 31 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 5 | 15 |
| Withdrew: Other | 0 | 0 | 0 | 3 | 1 |
Time to relapse is time between participant randomization in DB Phase and first documentation of relapse event by end of Month 12 of DB phase. Relapse is defined as: a) Psychiatric hospitalization; b) Positive and Negative Syndrome Scale (PANSS) total score: Increase of 25 percentage (%), 10 point increase in PANSS for 2 analysis separated by 3-7 days if score was greater than (\>) 40, less than or equal to (\<=)40; c) Participants inflicted knowing self-injury/shown violent behavior leading to suicide, clinically significant injury to him/herself or other person/property; d) Participants had suicidal/homicidal ideation/violent behavior that was clinically significant as per investigator; e) PANSS items P1- delusions, P2- conceptual disorganization, P3-hallucinatory behavior, P6- suspiciousness/ persecution, P7-hostility, G8-uncooperativeness: score: greater than or equal to (\>=)5, \>=6 for 2 analysis separated by 3-7 days on any items if maximum score for PANSS: \<=3 or 4, respectively.
| Days | DB PP3M | DB PP6M |
|---|---|---|
| Time to Relapse During the Double-Blind (DB) Phase | NA (NA to NA) | NA (NA to NA) |
The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale from 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).
| units on a scale | DB PP3M | DB PP6M |
|---|---|---|
| Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score | -1.6 ± 7.40 | -1.8 ± 8.92 |
CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. A higher score implies a more severe condition.
| units on a scale | DB PP3M | DB PP6M |
|---|---|---|
| Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score | 0.0 ± 0.63 | 0.0 ± 0.70 |
The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.
| units on a scale | DB PP3M | DB PP6M |
|---|---|---|
| Change From Baseline in the Personal and Social Performance (PSP) Scale Total Score | 1.1 ± 8.11 | 1.0 ± 7.12 |
Symptomatic remission was defined as achieving intensity level of mild or moderate on PANSS scale by all 8 items as the determinants for symptomatic remission: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, lack of spontaneity. The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent), 2 (minimal), 3 (mild), 4 (moderate), 5 (moderately severe), 6 (severe) and 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.
| Percentage of participants | DB PP3M | DB PP6M |
|---|---|---|
| Percentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase | 70.1 | 66.3 |
The SPSR Short Form 8a is a participant-reported outcome used to assess the satisfaction with participation in social roles. The participants were asked to rate 8 items on 5-point Likert scale, with scores ranging from 8 to 40, where higher scores represents higher satisfaction.
| units on a scale | DB PP3M | DB PP6M |
|---|---|---|
| Change From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score | 0.9 ± 7.15 | 0.6 ± 6.58 |
TSQM-9 consists of 9 questions to assess patients' satisfaction with medication using a range of responses from 1 (extremely dissatisfied) to (7 extremely satisfied). This patient reported outcome provides scores on three parts: effectiveness, convenience, and global satisfaction. The sum of the 9-questions were calculated and used for analysis. The total score ranges from 0 to 63, with higher scores indicating better treatment satisfaction.
| units on a scale | DB PP3M | DB PP6M |
|---|---|---|
| Effectiveness | 6.0 ± 21.18 | 3.6 ± 19.49 |
| Convenience | 3.4 ± 17.76 | 1.1 ± 15.30 |
| Overall satisfaction | 2.5 ± 19.29 | 0.5 ± 20.02 |
The SAS rates 10 items for general extrapyramidal symptoms (EPS) on a 5-point scale from 0 (normal) to 4 (extreme), including gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head rotation, Glabellar tap, tremor, and salivation. The SAS total score is the average score (total sum of item scores divided by the number of items) and ranges between 0 and 4. Negative change in score indicates improvement. Higher scores denote more severe condition of EPS.
| units on a scale | DB PP3M | DB PP6M |
|---|---|---|
| Change From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score | 0.00 (-0.6 to 2.1) | 0.00 (-0.6 to 1.5) |
BARS is used to rate observable, restless movements of drug induced akathisia and subjective awareness of restlessness and any distress associated with the akathisia. BARS consists of the following 4 items: objective assessment of akathisia symptoms, subjective assessment of the participants's awareness of inner restlessness, distress restlessness, and global clinical assessment of akathisia. First three items are rated on a 4-point scale ranging from 0 (no abnormal movements or absence of inner restlessness or no distress) to 3 (severe akathisia or awareness of intense compulsion to move most of the time or severe distress). The last item, the global clinical assessment of akathisia, is rated on a 6-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia).
| Participants | DB PP3M | DB PP6M |
|---|---|---|
| Global Clinical Assessment | 185 | 380 |
| Objective | 185 | 380 |
| Subjective (Awareness) | 185 | 380 |
| Subjective (Distress) | 185 | 380 |
AIMS is a 14-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 to 14 are yes/no questions regarding the global judgement and dental status of the participant. The total score is the sum of the scores for the 14 items and the possible total score ranges from 0 to 44. A higher total score is indicative of more severe dyskinetic movements.
| units on a scale | Double-blind (DB) PP3M | Double-blind (DB) PP6M |
|---|---|---|
| Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score | 0.0 (-3 to 2) | 0.0 (-7 to 14) |
The C-SSRS is a questionnaire used for suicide risk assessment. Affirmative or negative responses are provided to items 1 to 5 for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods \[not plan\] without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and items 6 to 10 for suicide behavior (6. Preparatory acts or behavior, 7. Aborted attempt, 8. Interrupted attempt, 9. Actual attempt, 10. Completed suicide). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation.
| Participants | DB PP3M | DB PP6M |
|---|---|---|
| Baseline (0= No event) | 221 | 477 |
| Baseline (1= Wish to be dead) | 3 | 0 |
| Baseline (2= Non-specific suicidal thought) | 0 | 1 |
| Baseline (3= Suicidal ideation-no intent) | 0 | 0 |
| Baseline (4= Ideation with intent, no plan) | 0 | 0 |
| Baseline (5= Ideation with plan/intent) | 0 | 0 |
| Baseline (6= Preparatory acts/behavior) | 0 | 0 |
| Baseline (7= Aborted attempt) | 0 | 0 |
| Baseline (8= Interrupted attempt) | 0 | 0 |
| Baseline (9= Actual attempt) | 0 | 0 |
| Baseline (10= Suicide) | 0 | 0 |
| End Point (0= No event) | 218 | 471 |
| End Point (1= Wish to be dead) | 1 | 1 |
| End Point (2= Non-specific suicidal thought) | 0 | 0 |
| End Point (3= Suicidal ideation-no intent) | 0 | 1 |
| End Point (4= Ideation with intent, no plan) | 1 | 0 |
| End Point (5= Ideation with plan/intent) | 1 | 2 |
| End Point (6= Preparatory acts/behavior) | 0 | 0 |
| End Point (7= Aborted attempt) | 0 | 0 |
| End Point (8= Interrupted attempt) | 0 | 0 |
| End Point (9= Actual attempt) | 0 | 1 |
| End Point (10= Suicide) | 0 | 0 |
Number of participants with treatment-emergent abnormal ECG values were reported. It includes heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute (bpm) , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec).
| Participants | DB PP3M | DB PP6M |
|---|---|---|
| Heart Rate value <=50 | 5 | 9 |
| Heart Rate value >=100 | 20 | 36 |
| PR Duration value >= 210 | 3 | 8 |
| QRS Duration value <= 50 | 0 | 0 |
| QRS Duration value >= 120 | 1 | 2 |
| QT Duration value <= 200 | 0 | 0 |
| QT Duration value >= 500 | 0 | 0 |
Change from baseline in BMI was reported.
| kilogram per meter square (kg/m^2) | DB PP3M | DB PP6M |
|---|---|---|
| Change From Baseline in the Body Mass Index (BMI) During DB Phase | 0.3 ± 1.78 | 0.0 ± 1.72 |
Change from baseline in waist circumference was reported.
| centimeter (cm) | DB PP3M | DB PP6M |
|---|---|---|
| Change From Baseline in the Waist Circumference During DB Phase | 0.82 ± 5.137 | 0.37 ± 5.157 |
Change from baseline in body weight was reported.
| kilogram (kg) | DB PP3M | DB PP6M |
|---|---|---|
| Change From Baseline in the Body Weight During DB Phase | 0.96 ± 5.103 | 0.10 ± 4.959 |
Change from baseline vital signs (pulse rate) were reported. This included supine pulse rate, standing pulse rate and supine-standing pulse rate.
| beats per minute (bpm) | Double-blind (DB) PP3M | Double-blind (DB) PP6M |
|---|---|---|
| Supine Pulse Rate | 1.2 ± 11.57 | 0.6 ± 11.56 |
| Standing Pulse Rate | 2.6 ± 12.28 | 0.9 ± 12.60 |
| Pulse Rate (Standing-Supine) | 1.5 ± 8.85 | 0.2 ± 8.31 |
Change from baseline in vital signs including SBP and DBP (supine/standing) were reported.
| millimetre of mercury (mmHg) | Double-blind (DB) PP3M | Double-blind (DB) PP6M |
|---|---|---|
| Supine SBP | -0.3 ± 13.14 | 0.6 ± 9.96 |
| Standing SBP | 0.8 ± 12.08 | 1.3 ± 10.40 |
| SBP (Standing-Supine) | 1.0 ± 9.83 | 0.6 ± 7.32 |
| Supine DBP | 0.1 ± 9.25 | -0.4 ± 7.49 |
| Standing DBP | 0.3 ± 9.39 | 0.4 ± 7.48 |
| DBP (Standing-Supine) | 0.2 ± 7.79 | 0.7 ± 6.43 |
The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).
| units on a scale | DB PP3M | DB PP6M |
|---|---|---|
| Positive Subscale Score | -0.1 ± 2.82 | -0.1 ± 3.30 |
| Negative Subscale Score | -0.6 ± 2.61 | -0.7 ± 2.70 |
| General Psychopathology Subscale Score | -0.9 ± 4.18 | -1.0 ± 4.86 |
Number of participants with clinically significant abnormal laboratory values in chemistry included alanine aminotransferase (Unit per Litre \[U/L\]), albumin (Gram per Litre \[g/L\]), alkaline phosphatase (U/L), aspartate aminotransferase (U/L), bicarbonate (millimoles per litre \[mmol/L\]), bilirubin (micromoles per litre \[umol/L\]), calcium (mmol/L), chloride (mmol/L), cholesterol (mmol/L), creatinine (umol/L), gamma glutamyl transferase (GGT) (U/L), glucose (mmol/L), high-density lipoproteins (HDL) cholesterol (mmol/L), low density lipoproteins (LDL) cholesterol (mmol/L), lactate dehydrogenase (U/L), phosphate (mmol/L), potassium (mmol/L), protein (mmol/L), sodium (mmol/L), triglycerides (mmol/L), urate (umol/L), urea nitrogen (mmol/L) were reported. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.
| Participants | DB PP3M | DB PP6M |
|---|---|---|
| Alanine Aminotransferase ABH | 0 | 1 |
| Albumin ABL | 0 | 0 |
| Albumin ABH | 0 | 0 |
| Alkaline Phosphatase ABH | 0 | 0 |
| Aspartate Aminotransferase ABH | 0 | 0 |
| Bicarbonate ABL | 0 | 3 |
| Bicarbonate ABH | 0 | 0 |
| Bilirubin ABH | 0 | 1 |
| Calcium ABL | 0 | 0 |
| Calcium ABH | 0 | 0 |
| Chloride ABL | 4 | 5 |
| Chloride ABH | 0 | 0 |
| Cholesterol ABH | 2 | 4 |
| Creatinine ABH | 0 | 0 |
| Gamma Glutamyl Transferase ABH | 0 | 2 |
| Glucose ABL | 1 | 0 |
| Glucose ABH | 1 | 5 |
| HDL Cholesterol ABL | 18 | 40 |
| LDL Cholesterol ABL | 33 | 44 |
| LDL Cholesterol ABH | 9 | 22 |
| Lactate Dehydrogenase ABH | 0 | 1 |
| Phosphate ABL | 1 | 8 |
| Phosphate ABH | 0 | 0 |
| Potassium ABL | 0 | 0 |
| Potassium ABH | 0 | 0 |
| Protein ABL | 0 | 1 |
| Sodium ABL | 1 | 0 |
| Sodium ABH | 0 | 0 |
| Triglycerides ABH | 4 | 6 |
| Urate ABL | 0 | 0 |
| Urate ABH | 1 | 4 |
| Urea Nitrogen ABH | 0 | 0 |
Number of participants with clinically significant abnormal laboratory values in hematology included hemoglobin (Hb), hematocrit (Hct), red blood cell (RBC) count, white blood cell (WBC) count with differential, platelets, hemoglobin A1c. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.
| Participants | DB PP3M | DB PP6M |
|---|---|---|
| Basophils ABL | 0 | 0 |
| Eosinophils ABL | 1 | 1 |
| Erythrocytes ABL | 1 | 0 |
| Erythrocytes ABH | 0 | 0 |
| Hematocrit ABL | 0 | 1 |
| Hematocrit ABH | 0 | 0 |
| Hemoglobin ABL | 1 | 0 |
| Hemoglobin ABH | 0 | 0 |
| Leukocytes ABL | 0 | 0 |
| Leukocytes ABH | 2 | 4 |
| Lymphocytes ABL | 0 | 2 |
| Lymphocytes ABH | 1 | 1 |
| Monocytes ABH | 0 | 0 |
| Neutrophils ABL | 1 | 0 |
| Neutrophils ABH | 0 | 0 |
| Platelets ABL | 0 | 0 |
| Platelets ABH | 0 | 0 |
Collected over Up to 2.5 Years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label (OL) PP1M/PP3M | 1/838 (0.1%) | 23/838 (2.7%) | 127/838 (15.2%) |
| Double-blind PP3M | 2/224 (0.9%) | 15/224 (6.7%) | 52/224 (23.2%) |
| Double-blind PP6M | 1/478 (0.2%) | 24/478 (5%) | 125/478 (26.2%) |
| Follow-up (FU) Phase PP3M | 0/42 (0%) | 1/42 (2.4%) | 1/42 (2.4%) |
| Follow-up Phase PP6M | 0/109 (0%) | 6/109 (5.5%) | 5/109 (4.6%) |
| Event | Open-Label (OL) PP1M/PP3M | Double-blind PP3M | Double-blind PP6M | Follow-up (FU) Phase PP3M | Follow-up Phase PP6M |
|---|---|---|---|---|---|
| Suicidal IdeationPsychiatric disorders | 3/838 | 2/224 | 1/478 | 1/42 | 0/109 |
| SchizophreniaPsychiatric disorders | 6/838 | 1/224 | 8/478 | 0/42 | 2/109 |
| Brain NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/838 | 0/224 | 0/478 | 0/42 | 1/109 |
| Nasal Sinus CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/838 | 0/224 | 0/478 | 0/42 | 1/109 |
| Mental DisorderPsychiatric disorders | 0/838 | 0/224 | 0/478 | 0/42 | 1/109 |
| Suicide AttemptPsychiatric disorders | 2/838 | 0/224 | 2/478 | 0/42 | 1/109 |
| Psychotic DisorderPsychiatric disorders | 3/838 | 2/224 | 1/478 | 0/42 | 0/109 |
| Sudden DeathGeneral disorders | 0/838 | 1/224 | 0/478 | 0/42 | 0/109 |
| CholelithiasisHepatobiliary disorders | 0/838 | 1/224 | 0/478 | 0/42 | 0/109 |
| Femur FractureInjury, poisoning and procedural complications | 0/838 | 1/224 | 0/478 | 0/42 | 0/109 |
| Event | Open-Label (OL) PP1M/PP3M | Double-blind PP3M | Double-blind PP6M | Follow-up (FU) Phase PP3M | Follow-up Phase PP6M |
|---|---|---|---|---|---|
| Injection Site PainGeneral disorders | 72/838 | 9/224 | 37/478 | 0/42 | 0/109 |
| Weight IncreasedInvestigations | 8/838 | 17/224 | 40/478 | 0/42 | 0/109 |
| HeadacheNervous system disorders | 16/838 | 12/224 | 32/478 | 0/42 | 0/109 |
| NasopharyngitisInfections and infestations | 22/838 | 13/224 | 22/478 | 1/42 | 4/109 |
| Upper Respiratory Tract InfectionInfections and infestations | 19/838 | 9/224 | 24/478 | 0/42 | 1/109 |
| Age, Continuous(years) | Open-Label (OL) PP1M/PP3M |
|---|---|
| Mean | 40.8 ± 11.68 |
| Sex: Female, Male(Participants) | Open-Label (OL) PP1M/PP3M |
|---|---|
| Female | 285 |
| Male | 553 |
| Ethnicity (NIH/OMB)(Participants) | Open-Label (OL) PP1M/PP3M |
|---|---|
| Hispanic or Latino | 118 |
| Not Hispanic or Latino | 710 |
| Unknown or Not Reported | 10 |
| Race (NIH/OMB)(Participants) | Open-Label (OL) PP1M/PP3M |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 111 |
| Native Hawaiian or Other Pacific Islander | 3 |
| Black or African American | 106 |
| White | 606 |
| More than one race | 5 |
| Unknown or Not Reported | 6 |
| Region of Enrollment(Participants) | Open-Label (OL) PP1M/PP3M |
|---|---|
| ARGENTINA | 55 |
| AUSTRALIA | 4 |
| BRAZIL | 90 |
| BULGARIA | 46 |
| CZECH REPUBLIC | 45 |
| FRANCE | 7 |
| HONG KONG | 4 |
| HUNGARY | 20 |
| INDIA | 42 |
| ITALY | 8 |
| KOREA, REPUBLIC OF | 4 |
| MALAYSIA | 22 |
| MEXICO | 23 |
| POLAND | 68 |
| RUSSIAN FEDERATION | 139 |
| SPAIN | 29 |
| TAIWAN | 31 |
| TURKEY | 26 |
| UKRAINE | 50 |
| UNITED STATES | 125 |
Showing the first 100 of 138 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in May 2020, 29 months.
Results were first posted in Dec 2021, 1 year 7 months after primary completion. A results delay was requested in May 2021.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 29 months is close to that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Janssen Research & Development, LLC →